Limitations Of The Method; Literature References; Warranty - peviva M30 Apoptosense ELISA Gebrauchsanweisung

Limitations of the Method

The clinical utility of ccK18 measurement in human blood samples as a prog-
nostic indicator and in the management of patients on therapy regimens has
not been fully established.
Grossly lipemic (≤ 1 250 mg/dL), icteric (≤ 12.5 mg/dL) or haemolysed
(≤ 50 mg/dL) samples do not interfere in the assay.

Literature References

1. Leers et al., J Pathol. 187, 1999, 567.
2. Schütte et al., Exp Cell Res. 297, 2004, 11.
3. Hägg et al., Invest New Drugs 20, 2002, 253.
4. Kramer et al., Cancer Res 64, 2004, 1751.
5. Olofsson et al., Cancer Biomarkers 5, 2009, 117.
6. Greystoke et al., Ann Oncol 19, 2008, 990.
Olofsson et al., Clin Cancer Res 13, 2007, 3198.
7.
8. Ueno et al., Eur J Cancer 39, 2003, 769.
For further references, please consult www.vlvbio.com/literature.

Warranty

The performance data presented here were obtained using the procedure
indicated. Any change or modification in this procedure as recommended
by the manufacturer may affect the results. In such event, the manufacturer
disclaims all warranties expressed, implied or statutory, including the implied
warranty of merchantability and the fitness for use. The manufacturer and its
authorized distributors, in such event, shall not be liable for damages indirect
or consequential.
M30 Apoptosense® ELISA
Page 15
En
Sv
De
Fr
It
Es